Conservative treatment for intermittent claudication
DOI: 10.32364/2587-6821-2021-5-4-212-217
M.R. Kuznetsov1,2, I.V. Reshetov1, S.V. Sapelkin3, N.V. Yasnopol’skaya2
1L.L. Levshin Institute of Cluster Oncology of the I.M. Sechenov First Moscow State Medical
University (Sechenov University), Moscow, Russian Federation
2S.S. Yudin City Clinical Hospital, Moscow, Russian Federation
3A.V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation
This paper discusses the issues emerging during the treatment of lower-limb arterial diseases and intermittent claudication. According to the international and Russian guidelines, the common management strategy for intermittent claudication is as follows: conservative treatment is recommended in patients without limiting intermittent claudication who can walk 30 m or more without pain. Drugs that are prescribed is these patients are addressed. No large well-designed studies on most of these drugs were conducted, therefore, it is challenging to assess their efficacy in patients with intermittent claudication. The authors focus on cilostazol that has the largest evidence base. This drug is included in the Russian and international clinical guidelines. Several students demonstrate that cilostazol provides antithrombotic effect, stabilizes atherosclerotic plaques, prevents hyperplasia of neointima and restenosis after vascular procedures, improves lipid metabolism, and significant ly increases pain-free walking distance (intermittent claudication distance). Recent studies show that cilostazol can be used in the complex treatment for COVID-19 due to pleiotropic mechanism of action.
Keywords: lower-limb arterial diseases, intermittent claudication, conservative treatment, cilostazol, COVID-19, restenosis, antiplatelet therapy.
For citation: Kuznetsov M.R., Reshetov I.V., Sapelkin S.V., Yasnopol’skaya N.V. Conservative treatment for intermittent claudication. Russian Medical Inquiry. 2021;5(4):212–217 (in Russ.). DOI: 10.32364/2587-6821-2021-5-4-212-217.
2. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей, 2019 г. (Электронный ресурс.) URL: http://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf. (дата обращения: 19.04.2021). [National guidelines for the diagnosis and treatment of lower limb artery diseases, 2019 (Electronic resource.) URL: http://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf. (access date: 09.04.2021) (in Russ.)].
3. Society for Vascular Surgery Lower Extremity Guidelines Writing Group. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 Suppl):2S–41S. DOI: 10.1016/j.jvs.2014.12.009.
4. Guideline on the Management of Patients with Lower Extremity Peripheral Artery Diseases: Executive Summary. American College of Cardiology / American Heart Association, 2016.
5. Nakamura Y., Nakamura К., Matsumura К. et al. Direct pyrogenic input from prostaglandin EP3 receptor-expressing preoptic neurons to the dorsomedial hypothalamus. Eur J Neurosci. 2005;22(12):3137–3146. DOI: 10.1111/j.1460-9568.2005.04515.x.
6. Tanigawa Y., Yamada Y., Nakamura К. et al. Preoperative disseminated intravascular coagulation complicated by thoracic aortic aneurysm treated using recombinant human soluble thrombomodulin: A case report. Medicine (Baltimore). 2021;100(9): e25044. DOI: 10.1097/MD.0000000000025044.
7. Elam M.B., Heckman J., Crouse J.R. et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942–1947. DOI: 10.1161/01.ATV.18.12.1942
8. Ishizaka N., Taguchi J., Kimura Y. et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis. 1999;142:41–46. DOI: 10.1016/S0021-9150 (98) 00147-6.
9. Ahn C.W., Lee H.C., Park S.W. et al. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2001;52:45–53. DOI: 10.1016/S0168-8227 (00) 00235-7.
10. Tsuchikane E., Katoh O., Sumitsuji S. et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J. 1998;135:495–502. DOI: 10.1016/S0002-8703 (98) 70327-8.
11. Take S., Matsutani M., Ueda H. et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1097–1099. DOI: 10.1016/S0002-9149 (97) 00052-0.
12. Yamasaki M., Hara K., Ikari Y. et al. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn. 1998;44:387–391. DOI: 10.1002/ (SICI) 1097-0304 (199808) 44:4<387: AID-CCD4>3.0.CO;2-0.
13. Kozuma K., Hara K., Yamasaki M. et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 2001;141:124–130. DOI: 10.1067/mhj.2001.111548.
14. Ge J., Han Y., Jiang H. et al. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. J Cardiovasc Pharmacol. 2005;46(2):162–166. DOI: 10.1097/01.fjc.0000167012.82930.8f.
15. Sekiya M., Funada J., Watanabe K. et al. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 1998;82:144–147. DOI: 10.1016/S0002-9149 (98) 00323-3.
16. Beebe H.G., Dawson D.L., Cutler B.S. et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041–2050. DOI: 10.1001/archinte.159.17.2041.
17. Dawson D.L., Cutler B.S., Hiatt W.R. et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–530. DOI: 10.1016/S0002-9343 (00) 00569-6.
18. Dawson D.L., DeMaioribus C.A., Hagino R.T. et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg. 1999;178:141–146. DOI: 10.1016/S0002-9610 (99) 00147-6.
19. Mohler E.R. III, Beebe H.G., Salles-Cuhna S. et al. Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc Med. 2001;6:151–156. DOI: 10.1177/1358836X0100600305.
20. Motta N.A.V., Autran L.J., Brazão S.C. et al. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. Int Immunopharmacol. 2021;92:107336. DOI: 10.1016/j.intimp.2020.107336.
21. Abosheasha M.A., El-Gowily A.H. Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M pro and spike protein: Drug repurposing approach. Drug Dev Res. 2021;82(2):217–229. DOI: 10.1002/ddr.21743.
22. Казанцев А.Н., Горюнов С.В., Ершова О.Б. и др. Рандомизированное исследование переносимости, безопасности и эффективности препарата Плетакс при перемежающейся хромоте. Ангиология и сосудистая хирургия. 2021;27(1):7–16. [Kazantsev A.N., Goryunov S.V., Ershova O.B. et al. A randomized study of the tolerability, safety and efficacy of Pletax in intermittent claudication. Angiologiya i sosudistaya khirurgiya. 2021;27(1):7–16 (in Russ.)]. DOI: 10.33529/angio2020405.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
